While apixaban is generally well-tolerated, it poses a risk for bleeding, the most significant adverse effect. This risk is heightened in individuals with concurrent use of other anticoagulants or antiplatelet agents. Hemorrhagic complications can range from minor bruising to life-threatening events such as intracranial hemorrhage or gastrointestinal bleeding. Monitoring for signs of bleeding is essential, especially in high-risk populations.
